Addex shareholders approve all resolutions at annual general meeting

Ad hoc announcement pursuant to art.   53 lr   geneva, switzerland, june 1 , 202 3 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2023 annual general meeting (agm).
ADXN Ratings Summary
ADXN Quant Ranking